ホーム>>Signaling Pathways>> Others>>Malic enzyme inhibitor ME1

Malic enzyme inhibitor ME1 (Synonyms: ME1)

カタログ番号GC38506

リンゴ酸酵素阻害剤 ME1 (ME1; 化合物 1) は、リンゴ酸酵素 (ME1) の強力な阻害剤であり、IC50 は 0.15 μM です。

Products are for research use only. Not for human use. We do not sell to patients.

Malic enzyme inhibitor ME1 化学構造

Cas No.: 522649-59-8

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$201.00
在庫あり
1mg
$88.00
在庫あり
5mg
$261.00
在庫あり
10mg
$449.00
在庫あり
25mg
$897.00
在庫あり
50mg
$1,530.00
在庫あり
100mg
$2,601.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM[1][2].

Malic enzyme inhibitor ME1 (ME1; ME1*) (50 μM; 72 hours) shows a significant reduction in total cell numbers[2]. Malic enzyme inhibitor ME1 shows a significant reduction in cell viability/metabolic activity in MTS cell[2]. Malic enzyme inhibitor ME1 dose-dependently reduces the number of colonies formed by both HCT116 and HT29 cells[2]. Cell Viability Assay[2] Cell Line: HCT116 and HT29 cell line

[1]. Zhang YJ, et al. In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors. Bioorg Med Chem Lett. 2006 Feb;16(3):525-8. Epub 2005 Nov 8. [2]. Fernandes L, et al. Malic Enzyme 1 (ME1) is pro-oncogenic in ApcMin/+ mice. Sci Rep. 2018 Sep 24;8(1):14268.

レビュー

Review for Malic enzyme inhibitor ME1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Malic enzyme inhibitor ME1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.